NXTCL — NextCell Pharma AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK144.81m
- SEK118.78m
- SEK13.70m
Annual cashflow statement for NextCell Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 16 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.8 | -35 | -41 | -43.2 | -51.8 |
| Depreciation | |||||
| Non-Cash Items | 0 | — | — | — | — |
| Unusual Items | |||||
| Changes in Working Capital | -1.19 | 1.25 | -3.27 | 4.42 | -2.44 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -25.6 | -33.3 | -43.8 | -37.8 | -50.9 |
| Capital Expenditures | -5.84 | -9.35 | -4.1 | -0.083 | -4.97 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | -0.003 | -0.001 | -0.3 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5.84 | -9.35 | -4.1 | -0.084 | -5.27 |
| Financing Cash Flow Items | -16.1 | 0.608 | 0.836 | -5.46 | -1.15 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 149 | 0.608 | 0.836 | 34.6 | 35.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 117 | -42.1 | -47.1 | -3.23 | -20.8 |